Clinical Chemistry 56: 186-193, 2010. First published December 3, 2009; 10.1373/clinchem.2009.127514
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
clinchem.2009.127514v1
56/2/186    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (1)
Google Scholar
Right arrow Articles by Ellington, A. A.
Right arrow Articles by Klee, G. G.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ellington, A. A.
Right arrow Articles by Klee, G. G.
Related Collections
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 2010;56:186-193.)
© 2010 American Association for Clinical Chemistry, Inc.

Mini-Reviews

Antibody-Based Protein Multiplex Platforms: Technical and Operational Challenges

Allison A. Ellington1, Iftikhar J. Kullo1, Kent R. Bailey2 and George G. Klee3,a

1 Division of Cardiovascular Diseases, 2 Division of Biomedical Statistics and Informatics, and 3 Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.

aAddress correspondence to this author at: Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 First St. SW, Rochester, MN 55905. E-mail: klee.george{at}mayo.edu.


Abstract

Background: The measurement of multiple protein biomarkers may refine risk stratification in clinical settings. This concept has stimulated development of multiplexed immunoassay platforms that provide multiple, parallel protein measurements on the same specimen.

Content: We provide an overview of antibody-based multiplexed immunoassay platforms and discuss technical and operational challenges. Multiplexed immunoassays use traditional immunoassay principles in which high-affinity capture ligands are immobilized in parallel arrays in either planar format or on microspheres in suspension. Development of multiplexed immunoassays requires rigorous validation of assay configuration and analytical performance to minimize assay imprecision and inaccuracy. Challenges associated with multiplex configuration include selection and immobilization of capture ligands, calibration, interference between antibodies and proteins and assay diluents, and compatibility of assay limits of quantification. We discuss potential solutions to these challenges. Criteria for assessing analytical multiplex assay performance include the range of linearity, analytical specificity, recovery, and comparison to a quality reference method. Quality control materials are not well developed for multiplexed protein immunoassays, and algorithms for interpreting multiplex quality control data are needed.

Summary: Technical and operational challenges have hindered implementation of multiplexed assays in clinical settings. Formal procedures that guide multiplex assay configuration, analytical validation, and quality control are needed before broad application of multiplexed arrays can occur in the in vitro diagnostic market.




The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
J. Brown, S. Nallamshetty, and J. Plutzky
Intersecting Vectors of Basic Science Research and Clinical Medicine: LOX-1?
Clin. Chem., April 1, 2010; 56(4): 499 - 501.
[Full Text] [PDF]